1. Chen, Xin, Dong, Thomas, Hu, Yuhui, Mazzulli, Joseph R, Gray, Steven J. . AAV9/MFSD8 gene therapy is effective in preclinical models of neuronal ceroid lipofuscinosis type 7 disease. In The Journal of clinical investigation, 132, . doi:10.1172/JCI146286. https://pubmed.ncbi.nlm.nih.gov/35025759/
2. Zare-Abdollahi, Davood, Bushehri, Ata, Alavi, Afagh, Jamali, Payman, Khorram Khorshid, Hamid Reza. 2019. MFSD8 gene mutations; evidence for phenotypic heterogeneity. In Ophthalmic genetics, 40, 141-145. doi:10.1080/13816810.2019.1592200. https://pubmed.ncbi.nlm.nih.gov/31006324/
3. Damme, Markus, Brandenstein, Laura, Fehr, Susanne, Hermans-Borgmeyer, Irm, Storch, Stephan. 2014. Gene disruption of Mfsd8 in mice provides the first animal model for CLN7 disease. In Neurobiology of disease, 65, 12-24. doi:10.1016/j.nbd.2014.01.003. https://pubmed.ncbi.nlm.nih.gov/24423645/
4. Geier, Ethan G, Bourdenx, Mathieu, Storm, Nadia J, Cuervo, Ana Maria, Yokoyama, Jennifer S. 2018. Rare variants in the neuronal ceroid lipofuscinosis gene MFSD8 are candidate risk factors for frontotemporal dementia. In Acta neuropathologica, 137, 71-88. doi:10.1007/s00401-018-1925-9. https://pubmed.ncbi.nlm.nih.gov/30382371/
5. Xiang, Qin, Cao, Yanna, Xu, Hongbo, Deng, Hao, Yuan, Lamei. 2021. Novel MFSD8 Variants in a Chinese Family with Nonsyndromic Macular Dystrophy. In Journal of ophthalmology, 2021, 6684045. doi:10.1155/2021/6684045. https://pubmed.ncbi.nlm.nih.gov/34457359/